Clinical trials
Phase 2 Digestive System Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2007 | 1 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 1 |
| 2013 | 1 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 4 |
| 2023 | 2 |
| 2024 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Terminated | 7 |
| Active, not recruiting | 5 |
| Unknown status | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
| Gilead Sciences | 2 |
| Mirum Pharmaceuticals, Inc. | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| Vertex Pharmaceuticals Incorporated | 2 |
| 89bio, Inc. | 1 |
| Adare Pharmaceuticals, Inc. | 1 |
| Aduro Biotech, Inc. | 1 |
| Akcea Therapeutics | 1 |
| Arizona State University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Digestive System Diseases | 38 |
| Gastrointestinal Diseases | 15 |
| Intestinal Diseases | 10 |
| Liver Diseases | 9 |
| Digestive System Neoplasms | 8 |
| Neoplasms | 7 |
| Neoplasms by Site | 7 |
| Colonic Diseases | 6 |
| Non-alcoholic Fatty Liver Disease | 6 |
| Pancreatic Diseases | 6 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.